Regeneron's Dual-Pronged Strategy in Obesity Therapy: Combination Treatment Approach Highlighted in Upcoming ADA & Endocrine Society Presentations

Regeneron Pharmaceuticals to Present Dual-Pronged Strategy in Obesity at the American Diabetes Association and Endocrine Society Meetings

Step 1: In June last year, an upfront payment of $80 million was made to Hansoh Pharma to acquire the global rights to olaretide, excluding mainland China. This drug is a dual GLP-1/GIP receptor agonist that has entered Phase III clinical trials. If all milestone targets are met, the total transaction value could reach $1.93 billion.

Step two, its antibody trevogrumab can block myostatin. The "Courage" trial showed that combining semaglutide with it could lead to greater fat reduction and less muscle loss.

Orforglipron resembles a deep out-of-the-money call option, while trevogrumab represents a unique competitive barrier and can be used in combination with various GLP-1 drugs.

The conference report will cover data on metabolic diseases and progress in the ophthalmology and rare disease product pipelines. Ophthalmic drugs are the company’s cash cow, with aflibercept and Dupixent reporting revenue growth in the first quarter of 2026: the former grew by 19% to reach $3.6 billion, while the latter saw its global sales increase by 33% to $4.9 billion.

Regeneron is leveraging its profits to build a portfolio of obesity drugs as a hedge against risk. Its price-to-earnings ratio is approximately 15x, with a market capitalization of around $65 billion. The average stock price year-to-date in 2026 is $742, compared to $619 in 2025.

The key focus moving forward is whether the dual-pronged strategy can support a valuation premium and whether both projects can succeed simultaneously; the company will release more data at the conference.

Translated content provided by third-party software.

Disclaimer: The market involves risks, and investment should be made with caution. This article is generated by an AI large model based on public information and does not represent the views of Sina Finance. All information, data, and charts in this article are for reference only and do not constitute any form of investment advice or basis for decision-making. Relevant information shall be subject to actual announcements. If you have any questions, please contact: biz@staff.sina.com.cn.

Responsible Editor: Xiaolang Express